Business Wire

TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 2022

27.5.2022 10:00:00 EEST | Business Wire | Press release

Share

TYAN®, an industry-leading server platform design manufacturer and MiTAC Computing Technology Corporation subsidiary, will exhibit its latest HPC platforms powered by 3rd Gen AMD EPYC™ Processors with AMD 3D V-Cache™ technology for data centers deployments at the ISC 2022 event from May 30th to June 1st at booth #D400.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220527005002/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

TYAN’s Server Platforms Powered by AMD EPYC 7003 Series Processors Provide the Best Foundation for Data Centers that Can be Tailored to Specific Workloads (Photo: Business Wire)

“The amount of data generated by humans and machines has increased exponentially and this requires a steady increase of data center compute performance, therefore, modern data centers need balanced hardware to efficiently manage growing data volumes,” said Danny Hsu, Vice President of MiTAC Computing Technology Corporation's Server Infrastructure Business Unit. “TYAN’s server platforms built upon AMD EPYC™ 7003 Series processors provide the best foundation for datacenters that can be tailored to specific workloads.”

Optimizing for HPC computation and database performance

Powered by 3rd Gen AMD EPYC processors, the Transport HX TN83-B8251 is a 2U dual-socket server with 16 DDR4-3200 DIMM slots and eight 3.5-inch hot-swap SATA or NVMe U.2 tool-less drive bays. The platform supports up to four double-wide GPU cards and two additional low-profile PCIe 4.0 x16 slots that provide optimized topology to improve HPC and deep learning performance.

The Transport CX TN73-B8037-X4S is a 2U multi-node server platform with four front-serviced compute nodes. Each node supports one AMD EPYC 7003 Series processor, four 2.5-inch tool-less NVMe/SATA drive bays, eight DDR4 DIMM slots, three internal cooling fans, two standard PCIe 4.0 x16 expansion slots, two internal NVMe M.2, and one OCP 2.0 LAN mezzanine slot. The platform is suited for high-density data center deployments and targets scale-out applications with large numbers of nodes.

The new Transport EX TE45-B8030 is a 2U edge server platform featuring a single AMD EPYC 7003 Series processor, eight DDR4-3200 DIMM slots and five PCIe 4.0 x16 slots. The platform accommodates six 2.5-inch SATA tool-less drive bays with up to two NVMe U.2 support. The TE45-B8030 can deliver high data throughput and address data acquired at the edge. Inclusion in this exhibit is the M7129-M942-2V network module with two SFP28 25GbE LAN ports that fit into a standard 2.5-inch drive bay.

Taking advantage of AMD EPYC CPU I/O capabilities, the Tomcat HX S8030 server motherboard brings full PCIe 4.0 support in a small ATX (12" x 9.8") form factor. The motherboard provides eight DDR4 DIMM slots, five PCIe 4.0 x16 slots, two SlimSAS 8x connectors for four NVMe, two NVMe M.2 slots, two 10GbE, and two GbE LAN ports.

The Tomcat CX S8253 is a dual-socket AMD EPYC 7003 Series processor-based server motherboard designed for 2U rackmount chassis deployment in EATX (12” x 13.4”) form factor. The motherboard supports 16 DDR4 DIMM slots, three PCIe 4.0 x16 slots, up to 16 SATA ports and two SlimSAS 8x connectors for four NVMe deployment.

Join TYAN booth at ISC 2022, booth #D400 or ISC Digital 2022 at: https://bit.ly/3FhIAYO

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

MiTAC Computing Technology Corporation/ Server Infrastructure Business Unit
Fenny Chen
fenny.chen@tyan.com.tw

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release

Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release

A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release

Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release

Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study

Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release

Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye